A phase II, randomized, noncomparative clinical trial of the effect of bevacizumab (BV) alone or in combination with irinotecan (CPT) on 6-month progression free survival (PFS6) in recurrent, treatment-refractory glioblastoma (GBM) - Cloughesy, TF (J Clin Oncol (Meeting Abstracts), 2008)
et al.